Analyzing Amedica (AMDA) and The Competition

Amedica (NASDAQ: AMDA) is one of 19 public companies in the “Medical Devices & Implants” industry, but how does it compare to its rivals? We will compare Amedica to similar businesses based on the strength of its institutional ownership, profitability, analyst recommendations, dividends, earnings, risk and valuation.

Analyst Ratings

This is a summary of recent recommendations for Amedica and its rivals, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Amedica 0 2 0 0 2.00
Amedica Competitors 126 738 1041 10 2.49

Amedica presently has a consensus target price of $60.00, indicating a potential upside of 1,590.14%. As a group, “Medical Devices & Implants” companies have a potential upside of 36.97%. Given Amedica’s higher possible upside, research analysts clearly believe Amedica is more favorable than its rivals.

Insider and Institutional Ownership

62.5% of Amedica shares are owned by institutional investors. Comparatively, 54.4% of shares of all “Medical Devices & Implants” companies are owned by institutional investors. 0.1% of Amedica shares are owned by company insiders. Comparatively, 10.3% of shares of all “Medical Devices & Implants” companies are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.


This table compares Amedica and its rivals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Amedica -71.07% -73.86% -36.96%
Amedica Competitors -100.14% -92.44% -29.75%

Volatility and Risk

Amedica has a beta of -2.08, meaning that its stock price is 308% less volatile than the S&P 500. Comparatively, Amedica’s rivals have a beta of 0.31, meaning that their average stock price is 69% less volatile than the S&P 500.

Valuation & Earnings

This table compares Amedica and its rivals top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Amedica $15.23 million -$14.76 million N/A
Amedica Competitors $1.67 billion $207.76 million 61.76

Amedica’s rivals have higher revenue and earnings than Amedica.


Amedica rivals beat Amedica on 8 of the 12 factors compared.

Amedica Company Profile

Amedica Corporation is a commercial biomaterial company. The Company is a vertically integrated silicon nitride orthopedic medical device manufacturer. It is focused on using its silicon nitride ceramic technology platform to develop, manufacture and sell a range of medical devices. It is also engaged in developing wear- and corrosion-resistant implant components for hip and knee arthroplasty. The Company markets its Valeo family of silicon nitride interbody spinal fusion devices in the United States, Europe and Brazil for use in the cervical and thoracolumbar areas of the spine. In addition to its silicon nitride-based spinal fusion products, it markets a line of non-silicon nitride spinal surgery products, which allows the Company to provide surgeons and hospitals with a solution for spinal procedures. Its Valeo interbody spinal fusion devices include Anterior Lumbar, Posterior Lumbar, Oblique Lumbar, Transforaminal Lumbar, Lateral Lumbar, Cervical and Corpectomy.

Receive News & Ratings for Amedica Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amedica and related companies with's FREE daily email newsletter.

Leave a Reply